Bulletin
Investor Alert

London Markets Open in:

Asia Markets Currencies US Market Snapshot

Cerecor Inc.

NAS: CERC

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cerecor Inc.

After Hours

 --Quotes are delayed by 20 min

Jun 3, 2020, 7:58 p.m.

CERC
/zigman2/quotes/201368871/composite

$

2.60

Change

0.00 0.00%

Volume

Volume 605

Quotes are delayed by 20 min

/zigman2/quotes/201368871/composite

Previous close

$ 2.92

$ 2.60

Change

-0.32 -10.96%

Day low

Day high

$2.52

$2.94

Open

52 week low

52 week high

$1.52

$6.19

Open

Company Description

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company...

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Valuation

Price to Sales Ratio

34.24

Price to Book Ratio

11.40

Enterprise Value to Sales

32.76

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

375,020.00

Income Per Employee

-903,931.00

Receivables Turnover

0.97

Total Asset Turnover

0.13

Liquidity

Current Ratio

1.46

Quick Ratio

1.46

Cash Ratio

0.93

Profitability

Gross Margin

63.08

Operating Margin

-281.37

Pretax Margin

-236.88

Net Margin

-241.04

Return on Assets

-30.57

Return on Equity

-77.66

Return on Total Capital

-64.88

Return on Invested Capital

-56.75

Capital Structure

Total Debt to Total Equity

6.04

Total Debt to Total Capital

5.69

Total Debt to Total Assets

3.51

Long-Term Debt to Equity

5.30

Long-Term Debt to Total Capital

4.99

Officers and Executives

Name Age Officer Since Title
Mr. Michael F. Cola 59 2020 Chief Executive Officer & Director
Dr. Simon C. Pedder 58 2018 Lead Independent Director
Mr. Christopher Sullivan 35 2018 Vice President-Finance
Dr. Garry Arthur Neil 65 2020 Chief Medical Officer
Dr. H. Jeffrey Wilkins 57 2020 Chief Development Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/09/2020 Simon C. Pedder
Executive Chairman of the Bd; Director 		20,901   Derivative/Non-derivative trans. at $2.57 per share. 53,715
04/03/2020 Armistice Capital LLC
Director 		4,280   Acquisition at $2.16 per share. 9,244
03/31/2020 Armistice Capital LLC
Director 		26,611   Acquisition at $2.33 per share. 62,003
03/30/2020 Armistice Capital LLC
Director 		49,303   Acquisition at $2.35 per share. 115,862
03/27/2020 Armistice Capital LLC
Director 		36,000   Acquisition at $2.43 per share. 87,480
03/23/2020 Armistice Capital LLC
Director 		1,374   Acquisition at $2.52 per share. 3,462
03/20/2020 Armistice Capital LLC
Director 		9,626   Acquisition at $2.5 per share. 24,065
03/19/2020 Armistice Capital LLC
Director 		1,567   Acquisition at $2.6 per share. 4,074
03/18/2020 Armistice Capital LLC
Director 		8,433   Acquisition at $1.91 per share. 16,107
03/18/2020 Armistice Capital LLC
Director 		20,000   Acquisition at $1.91 per share. 38,200
02/03/2020 Armistice Capital LLC
Director 		275,000   Acquisition at $3.98 per share. 1,094,500
02/03/2020 Armistice Capital LLC
Director 		0   Acquisition at $0 per share. 0
02/03/2020 Armistice Capital LLC
Director 		981,282   Acquisition at $3.98 per share. 3,905,502
02/03/2020 Michael F. Cola
Chief Executive Officer; Director 		75,746   Award at $0 per share. 0
02/03/2020 Garry Arthur Neil
Chief Medical Officer 		72,282   Award at $0 per share. 0
/news/latest/company/us/cerc

MarketWatch News on CERC

  1. Big Stock Buys at Winnebago, National CineMedia

    9:40 p.m. March 27, 2020

    - Barron's Online

  2. Cerecor started at outperform with $11 stock price target at Oppenheimer

    9:52 a.m. Jan. 10, 2020

    - Tomi Kilgore

  4. Starboard Value Urges Zayo Group to Sell Itself

    1:10 a.m. March 16, 2019

    - Barron's Online

  5. There’s Value in Damaged Papa John’s Pizza

    8:00 p.m. Oct. 5, 2018

    - Barron's Online

  7. Cerecor Inc. shares drop 37% after midstage trial failure

    9:14 a.m. Dec. 5, 2016

    - Emma Court

  8. Cerecor's stock extends slide, plunges 37% premarket after failed drug trial

    9:09 a.m. Dec. 5, 2016

    - Tomi Kilgore

  9. Cerecor says mid-stage trial of treatment for nicotine withdrawal missed its target

    9:05 a.m. Dec. 5, 2016

    - Ciara Linnane

  10. Cerecor's stock tumbles 14% premarket after drug trial fails to meet primary endpoint

    9:05 a.m. Dec. 5, 2016

    - Tomi Kilgore

  11. Cerecor's stock on track to open at all-time low

    9:06 a.m. Dec. 5, 2016

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cerc

Other News on CERC

  1. Cerecor (CERC) Investor Presentation - Slideshow

    6:11 p.m. June 3, 2020

    - Seeking Alpha

  3. ARNC, ALXN among premarket gainers

    9:20 a.m. May 28, 2020

    - Seeking Alpha

  4. Cerecor on go with study of CERC-002 in COVID-19 patients

    7:18 a.m. May 28, 2020

    - Seeking Alpha

  5. NVAX, LK among premarket ganers

    9:26 a.m. May 26, 2020

    - Seeking Alpha

  6. NVAX, LK among premarket gainers

    9:26 a.m. May 26, 2020

    - Seeking Alpha

  8. Aytu: A One-Trick Play

    6:24 a.m. April 1, 2020

    - Seeking Alpha

  10. Cerecor up 29% on exploratory work in COVID-19

    7:36 a.m. March 26, 2020

    - Seeking Alpha

  11. Circling Around On Cerecor

    3:25 p.m. March 23, 2020

    - Seeking Alpha

  12. Daily Insider Ratings Round Up 3/19/20

    4:34 p.m. March 20, 2020

    - Seeking Alpha

  13. Daily Insider Ratings Round Up 2/5/20

    2:15 p.m. Feb. 6, 2020

    - Seeking Alpha

  16. Cerecor to acquire Aevi Genomic Medicine

    12:56 p.m. Dec. 5, 2019

    - Seeking Alpha

  17. 10-Q: CERECOR INC.

    5:16 p.m. Nov. 14, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  18. Aytu Bio acquires prescription product portfolio for $17M

    7:32 a.m. Oct. 14, 2019

    - Seeking Alpha

  19. Daily Insider Ratings Round Up 9/6/19

    5:08 p.m. Sept. 9, 2019

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Cerecor, Inc.

540 Gaither Road

Suite 400

Rockville, Maryland 20850

Phone

1 4105228707

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

View SEC Filings

Revenue

$6.75M

Net Income

$-16.27M

Employees

18.00

Annual Report for CERC

/news/pressrelease/company/us/cerc

Press Releases on CERC

  6. Cerecor Reports Q1 2020 Results and Update

    6:30 a.m. May 7, 2020

    - GlobeNewswire

  8. Aurinia Appoints Joe Miller as Chief Financial Officer

    6:05 a.m. April 27, 2020

    - BusinessWire - BZX

  9. Cerecor Announces Changes to Board of Directors

    1:45 p.m. April 24, 2020

    - GlobeNewswire

  13. Cerecor Reports 2019 Results

    6:30 a.m. March 11, 2020

    - GlobeNewswire

  16. Cerecor and Aevi Genomic Medicine Complete Merger

    5:15 p.m. Feb. 3, 2020

    - GlobeNewswire

  17. Cerecor and Aevi Genomic Medicine Complete Merger

    5:15 p.m. Feb. 3, 2020

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.